Alvotech (NASDAQ:ALVO) Stock Price Up 4.8% – Here’s What Happened

Alvotech (NASDAQ:ALVO – Get Free Report) shares shot up 4.8% during mid-day trading on Monday. The stock traded as high as $4.32 and last traded at $4.39. 110,448 shares were traded during mid-day trading, a decline of 86% from the average session volume of 779,760 shares. The stock had previously closed at $4.19.

Analyst Ratings Changes

Several analysts have commented on the stock. Evercore began coverage on shares of Alvotech in a report on Friday, August 14th. They set an “outperform” rating on the stock. Weiss Ratings raised shares of Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Jefferies Financial Group began coverage on shares of Alvotech in a report on Tuesday, November 10th. They issued a “buy” rating and a $9.00 price target for the company. Barclays raised shares of Alvotech from an “underweight” rating to an “overweight” rating and increased their price objective for the stock from $4.00 to $8.00 in a research report on Wednesday, September 16th. Finally, UBS Group set a $8.00 price objective on shares of Alvotech in a report on Wednesday, September 16th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.40.

Get Our Latest Stock Analysis on ALVO

Alvotech Stock Up 5.8%

The stock has a fifty day moving average of $5.23 and a 200-day moving average of $4.20. The firm has a market capitalization of $1.34 billion, a P/E ratio of -5.41 and a beta of 0.24.

Alvotech (NASDAQ:ALVO – Get Free Report) last released its quarterly earnings results on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $111.60 million for the quarter, compared to analyst estimates of $123.45 million. Sell-side analysts predict that Alvotech will post -0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Alvotech

A number of large investors have recently modified their holdings of the business. Ulland Investment Advisors LLC lifted its stake in shares of Alvotech by 5.0% during the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock worth $667,000 after buying an additional 5,500 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of Alvotech during the 3rd quarter worth about $68,000. Commonwealth Equity Services LLC acquired a new position in Alvotech in the 3rd quarter valued at about $69,000. China Universal Asset Management Co. Ltd. grew its stake in Alvotech by 24.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock valued at $365,000 after buying an additional 12,049 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Alvotech in the 3rd quarter valued at about $100,000.

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

See Also

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.